---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-151007"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T14:30:17.480492+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences Q1 net loss $2.6M; cash $40M to fund operations for 24 months

## Summary
- Net loss of $2.6M ($0.17 per share) vs $4.8M ($0.36) in Q1 2021; R&D spend down to $0.7M on wind-down of FB-401.
- Cash and cash equivalents $40.0M; cash burn $2.0M in Q1; sufficient for at least 24 months.
- Lead asset FB-102 for autoimmune diseases expected to enter clinic in H2 2023.
- Appointed Stephen Doberstein, Ph.D. and Barbara Finck, M.D. to board of directors.
- 14.8M shares outstanding as of March 31, 2022.

## SEC filing metadata
- accession: 0001193125-22-151007
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312522151007/0001193125-22-151007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312522151007/d358978d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-151007
- JSON: https://secwatch.observer/filing/0001193125-22-151007.json
- Plain text: https://secwatch.observer/filing/0001193125-22-151007.txt

## Key facts
- Executive change
  Stephen K. Doberstein was appointed as Director at Forte Biosciences, Inc..
  - Action: appointed
  - Role: Director
  source text: Appointment of Director On May 12, 2022, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Governance Committee of the Board, appointed Stephen K. Doberstein, Ph.D. to the Board, effective May 12, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419041/000119312522151007/0001193125-22-151007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.